Emerging drugs for malaria

Bibliography

• Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009;22:430-5
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). World Malaria Report 2011; 2011
   Google Scholar
• Vitoria M, Granich R, Gilks CF, The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 2009;131:844-8
   PubMed Web of Science ®Google Scholar
• WHO. Malaria. Available from: http://www.who.int/mediacentre/factsheets/fs094/en/index.html [Last accessed 20 April 2011]
   Google Scholar
• Greenwood BM, Targett GAT. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 2011;17:1600-7
   Google Scholar
• Hill AVS. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011;366:2806-14
   PubMed Web of Science ®Google Scholar
• Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev Vaccines 2011;10:589-99
   PubMed Web of Science ®Google Scholar
• Agnandji ST, Lell B, Soulanoudjingar SS, First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011;365:1863-75
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67
   PubMed Web of Science ®Google Scholar
• Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009;361:540-1
   PubMed Web of Science ®Google Scholar
• Noedl H, Se Y, Schaecher K, Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619-20
   PubMed Web of Science ®Google Scholar
• Cheeseman IH, Miller BA, Nair S, A major genome region underlying artemisinin resistance in malaria. Science 2012;336:79-82
   PubMed Web of Science ®Google Scholar
• Brewer TG, Grate SJ, Peggins JO, Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994;51:251-9
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria, second edition. 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf
   Google Scholar
• Dondorp AM, Fanello CI, Hendriksen ICE, Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-57
   PubMed Web of Science ®Google Scholar
• World Health Organization. World malaria report. 2010. Available from: http://www.who.int/malaria/world_malaria_report_2010/en/index.html
   Google Scholar
• Elderfield RC, Gensler WJ, Head JD, Alkylaminoalkyl Derivatives of 8-Aminoquinoline1. JACS 1946;68:1524-9
   PubMedGoogle Scholar
• Krotoski WA, Garnham PC, Cogswell FB, Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am J Trop Med Hyg 1986;35:263-74
   PubMed Web of Science ®Google Scholar
• Arnold J, Alving AS, Hockwald RS, The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 1955;46:391-7
   PubMed Web of Science ®Google Scholar
• Pukrittayakamee S, Chotivanich K, Chantra A, Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 2004;48:1329-34
   PubMed Web of Science ®Google Scholar
• Pukrittayakamee S, Vanijanonta S, Chantra A, Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 1994;169:932-5
   PubMed Web of Science ®Google Scholar
• Fletcher KA, Evans DA, Gilles HM, Studies on the pharmacokinetics of primaquine. Bull World Health Organ 1981;59:407-12
   PubMed Web of Science ®Google Scholar
• Smithuis F, Kyaw MK, Phe O, Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010;10:673-81
   PubMed Web of Science ®Google Scholar
• Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ 1981;59:391-5
   PubMed Web of Science ®Google Scholar
• Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61
   PubMed Web of Science ®Google Scholar
• Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem 2009;44:937-53
   PubMed Web of Science ®Google Scholar
• Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis 2004;39:1336-45
   PubMed Web of Science ®Google Scholar
• Aponte JJ, Schellenberg D, Egan A, Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009;374:1533-42
   PubMed Web of Science ®Google Scholar
• Grobusch MP, Egan A, Gosling RD, Newman RD. Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 2007;20:613-20
   PubMed Web of Science ®Google Scholar
• Rogerson SJ, Chaluluka E, Kanjala M, Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997-99. Trans R Soc Trop Med Hyg 2000;94:549-53
   PubMed Web of Science ®Google Scholar
• Verhoeff FH, Brabin BJ, Chimsuku L, An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998;92:141-50
   PubMed Web of Science ®Google Scholar
• Schultz LJ, Steketee RW, Macheso A, The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994;51:515-22
   PubMed Web of Science ®Google Scholar
• Talisuna AO, Bloland P, D’Alessandro U. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 2004;17:235-54
   PubMed Web of Science ®Google Scholar
• Dixon KE, Williams RG, Pongsupat T, A comparative trial of Mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar. Trans R Soc Trop Med Hyg 1982;76:664-7
   PubMed Web of Science ®Google Scholar
• Sridaran S, McClintock SK, Syphard LM, Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J 2010;9:247
   PubMed Web of Science ®Google Scholar
• ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007;297:2603-16
   PubMed Web of Science ®Google Scholar
• Gosling RD, Cairns ME, Chico RM, Chandramohan D. Intermittent preventive treatment against malaria: an update. Expert Rev Anti Infect Ther 2010;8:589-606
   PubMed Web of Science ®Google Scholar
• Alonso PL, Bassat Q, Binka F, A Research Agenda for Malaria Eradication: Drugs. PLoS Med 2011;8:e1000402
   PubMedGoogle Scholar
• Onwujekwe O, Kaur H, Dike N, Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malar J 2009;8:22
   PubMed Web of Science ®Google Scholar
• Newton PN, Fernandez FM, Plancon A, A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008;5:e32
   PubMed Web of Science ®Google Scholar
• Sengaloundeth S, Green MD, Fernandez FM, A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR - implications for therapeutic failure and drug resistance. Malar J 2009;8:172
   PubMed Web of Science ®Google Scholar
• Bate R, Tren R, Mooney L, Pilot study of essential drug quality in two major cities in India. PLoS ONE 2009;4:e6003
   PubMed Web of Science ®Google Scholar
• The Gobal Fund. Affordable Medicines Facility - malaria (AMFm). Available from: http://www.theglobalfund.org/en/amfm/
   Google Scholar
• Matowe L, Adeyi O. The quest for universal access to effective malaria treatment: how can the AMFm contribute? Malar J 2010;9:274
   PubMedGoogle Scholar
• $225 million partnership to bring effective malaria drugs to all who need them - The Global Fund to Fight AIDS, Tuberculosis and Malaria. Available from: http://www.theglobalfund.org/en/mediacenter/pressreleases/USD225_million_partnership_to_bring_effective_malaria_drugs_to_all_who_need_them/ [Last accessed 18 December 2011]
   Google Scholar
• Gamo F-J, Sanz LM, Vidal J, Thousands of chemical starting points for antimalarial lead identification. Nature 2010;465:305-10
   PubMed Web of Science ®Google Scholar
• Guiguemde WA, Shelat AA, Bouck D, Chemical genetics of Plasmodium falciparum. Nature 2010;465:311-15
   PubMed Web of Science ®Google Scholar
• Plouffe D, Brinker A, McNamara C, In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci USA 2008;105:9059-64
   PubMed Web of Science ®Google Scholar
• Meister S, Plouffe DM, Kuhen KL, Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 2011;334:1372-7
   PubMed Web of Science ®Google Scholar
• Krugliak M, Zhang J, Ginsburg H. Intraerythrocytic Plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins. Mol Biochem Parasitol 2002;119:249-56
   PubMed Web of Science ®Google Scholar
• Lew VL, Tiffert T, Ginsburg H. Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood 2003;101:4189-94
   PubMed Web of Science ®Google Scholar
• Liu J, Istvan ES, Gluzman IY, Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc Natl Acad Sci USA 2006;103:8840-5
   PubMed Web of Science ®Google Scholar
• Egan TJ. Haemozoin formation. Mol Biochem Parasitol 2008;157:127-36
   PubMed Web of Science ®Google Scholar
• Bray PG, Martin RE, Tilley L, Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol Microbiol 2005;56:323-33
   PubMed Web of Science ®Google Scholar
• Lakshmanan V, Bray PG, Verdier-Pinard D, A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 2005;24:2294-305
   PubMed Web of Science ®Google Scholar
• Martin RE, Marchetti RV, Cowan AI, Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 2009;325:1680-2
   PubMed Web of Science ®Google Scholar
• Sidhu ABS, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002;298:210-13
   PubMed Web of Science ®Google Scholar
• Summers RL, Martin RE. Functional characteristics of the malaria parasite's “chloroquine resistance transporter”: implications for chemotherapy. Virulence 2010;1:304-8
   PubMed Web of Science ®Google Scholar
• Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006;27:594-601
   PubMed Web of Science ®Google Scholar
• Dubar F, Khalife J, Brocard J, Ferroquine, an ingenious antimalarial drug: thoughts on the mechanism of action. Molecules 2008;13:2900-7
   PubMed Web of Science ®Google Scholar
• Dubar F, Egan TJ, Pradines B, The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. ACS Chem Biol 2011;6:275-87
   PubMed Web of Science ®Google Scholar
• Ding XC, Beck H-P, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 2011;27:73-81
   PubMed Web of Science ®Google Scholar
• Li J, Zhou B. Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules 2010;15:1378-97
   PubMed Web of Science ®Google Scholar
• O’Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin–the debate continues. Molecules 2010;15:1705-21
   PubMed Web of Science ®Google Scholar
• Eckstein-Ludwig U, Webb RJ, Van Goethem IDA, Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003;424:957-61
   PubMed Web of Science ®Google Scholar
• Meunier B, Robert A. Heme as trigger and target for trioxane-containing antimalarial drugs. Acc Chem Res 2010;43:1444-51
   PubMed Web of Science ®Google Scholar
• Yang YZ, Asawamahasakda W, Meshnick SR. Alkylation of human albumin by the antimalarial artemisinin. Biochem Pharmacol 1993;46:336-9
   PubMed Web of Science ®Google Scholar
• Yang YZ, Little B, Meshnick SR. Alkylation of proteins by artemisinin. Effects of heme, pH, and drug structure. Biochem Pharmacol 1994;48:569-73
   PubMed Web of Science ®Google Scholar
• del Pilar Crespo M, Avery TD, Hanssen E, Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob Agents Chemother 2008;52:98-109
   PubMed Web of Science ®Google Scholar
• Li W, Mo W, Shen D, Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 2005;1:e36
   Google Scholar
• Wang J, Huang L, Li J, Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010;5:e9582
   PubMed Web of Science ®Google Scholar
• Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997;94:13944-9
   PubMed Web of Science ®Google Scholar
• Dieckmann A, Jung A. The mechanism of pyrimethamine resistance in Plasmodium falciparum. Parasitology 1986;93(Pt 2):275-8
   PubMedGoogle Scholar
• Huennekens FM.. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994;34:397-419
   PubMedGoogle Scholar
• Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011;12:1449-63
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults in resource-limited settings Recommendations for a public health approach. 2006. Available from: http://www.who.int/hiv/pub/guidelines/WHO%20CTX.pdf
   Google Scholar
• Kapito-Tembo A, Meshnick SR, van Hensbroek MB, Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. J Infect Dis 2011;203:464-72
   PubMed Web of Science ®Google Scholar
• Newman PM, Wanzira H, Tumwine G, Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J 2009;8:254
   PubMedGoogle Scholar
• Dahl EL, Rosenthal PJ. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol 2008;24:279-84
   PubMed Web of Science ®Google Scholar
• Pradel G, Schlitzer M. Antibiotics in malaria therapy and their effect on the parasite apicoplast. Curr Mol Med 2010;10:335-49
   PubMed Web of Science ®Google Scholar
• Botte CY, Dubar F, McFadden GI, Plasmodium falciparum Apicoplast Drugs: targets or Off-Targets? Chem Rev 2011;112:1269-83
   PubMed Web of Science ®Google Scholar
• Yeh E, DeRisi JL. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 2011;9:e1001138
   PubMed Web of Science ®Google Scholar
• Jomaa H, Wiesner J, Sanderbrand S, Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 1999;285:1573-6
   PubMed Web of Science ®Google Scholar
• Dahl EL, Shock JL, Shenai BR, Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2006;50:3124-31
   PubMed Web of Science ®Google Scholar
• Dahl EL, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother 2007;51:3485-90
   PubMed Web of Science ®Google Scholar
• Fichera ME, Roos DS. A plastid organelle as a drug target in apicomplexan parasites. Nature 1997;390:407-9
   PubMed Web of Science ®Google Scholar
• Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 2007;152:181-91
   PubMed Web of Science ®Google Scholar
• Kremsner PG, Winkler S, Brandts C, Curing of chloroquine-resistant malaria with clindamycin. Am J Trop Med Hyg 1993;49:650-4
   PubMed Web of Science ®Google Scholar
• Search of: azithromycin malaria - List Results - ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/results?term=azithromycin+malaria [Last accessed 16 December 2011]
   Google Scholar
• Maude RJ, Woodrow CJ, White LJ. Artemisinin Antimalarials: preserving the “Magic Bullet”. Drug Dev Res 2010;71:12-19
   PubMed Web of Science ®Google Scholar
• Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009;7:864-74
   PubMed Web of Science ®Google Scholar
• Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77:181-92
   PubMed Web of Science ®Google Scholar
• Jambou R, Le Bras J, Randrianarivelojosia M. Pitfalls in new artemisinin-containing antimalarial drug development. Trends Parasitol 2011;27:82-90
   PubMed Web of Science ®Google Scholar
• Hess KM, Goad JA, Arguin PM. Intravenous artesunate for the treatment of severe malaria. Ann Pharmacother 2010;44:1250-8
   PubMed Web of Science ®Google Scholar
• Douglas NM, Anstey NM, Angus BJ, Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405-16
   PubMed Web of Science ®Google Scholar
• Interactive science portfolio MMV. Available from: http://www.mmv.org/research-development/science-portfolio [Last accessed 24 April 2011]
   Google Scholar
• Pooley S, Fatih FA, Krishna S, Artemisone uptake in Plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 2011;55:550-6
   PubMed Web of Science ®Google Scholar
• Hofer S, Brun R, Maerki S, In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum. J Antimicrob Chemother 2008;62:1061-4
   PubMed Web of Science ®Google Scholar
• Vennerstrom JL, Arbe-Barnes S, Brun R, Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004;430:900-4
   PubMed Web of Science ®Google Scholar
• Valecha N, Looareesuwan S, Martensson A, Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 2010;51:684-91
   PubMed Web of Science ®Google Scholar
• Gautam A, Ahmed T, Sharma P, Pharmacokinetics and Pharmacodynamics of Arterolane Maleate Following Multiple Oral Doses in Adult Patients With P. Falciparum Malaria. J Clin Pharmacol 2010. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21148048 [Last Accessed 20 April 2011]
   Google Scholar
• Maerki S, Brun R, Charman SA, In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. J Antimicrob Chemother 2006;58:52-8
   PubMed Web of Science ®Google Scholar
• Snyder C, Chollet J, Santo-Tomas J, In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp Parasitol 2007;115:296-300
   PubMed Web of Science ®Google Scholar
• Charman SA, Arbe-Barnes S, Bathurst IC, Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011;108:4400-5
   PubMed Web of Science ®Google Scholar
• Barends M, Jaidee A, Khaohirun N, In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J 2007;6:81
   PubMedGoogle Scholar
• Henry M, Briolant S, Fontaine A, In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum. AntimicrobAgents Chemother 2008;52:2755-9
   PubMed Web of Science ®Google Scholar
• Kreidenweiss A, Kremsner PG, Dietz K, Mordmuller B. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 2006;75:1178-81
   PubMed Web of Science ®Google Scholar
• Leimanis ML, Jaidee A, Sriprawat K, Plasmodium vivax susceptibility to ferroquine. Antimicrob Agents Chemother 2010;54:2228-30
   PubMed Web of Science ®Google Scholar
• Mombo-Ngoma G, Supan C, Dal-Bianco MP, Phase I randomized dose-ascending placebo-controlled trials of ferroquine–a candidate anti-malarial drug–in adults with asymptomatic Plasmodium falciparum infection. Malar J 2011;10:53
   PubMed Web of Science ®Google Scholar
• Search of: ferroquine - List Results - ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/results?term=ferroquine [Last accessed 16 December 2011]
   Google Scholar
• Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998;58:645-9
   PubMed Web of Science ®Google Scholar
• Walsh DS, Looareesuwan S, Wilairatana P, Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis 1999;180:1282-7
   PubMed Web of Science ®Google Scholar
• Peters W, Robinson BL, Milhous WK. The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605. Ann Trop Med Parasitol 1993;87:547-52
   PubMed Web of Science ®Google Scholar
• Walsh DS, Wilairatana P, Tang DB, Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis 2004;39:1095-103
   PubMed Web of Science ®Google Scholar
• Kitchener S, Nasveld P, Edstein MD. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg 2007;76:494-6
   PubMed Web of Science ®Google Scholar
• Search of: tafenoquine - List Results - ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/results?term=tafenoquine [Last accessed 16 December 2011]
   Google Scholar
• Nasveld PE, Edstein MD, Reid M, Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob. Agents Chemother 2010;54:792-8
   PubMed Web of Science ®Google Scholar
• Hale BR, Owusu-Agyei S, Fryauff DJ, A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003;36:541-9
   PubMed Web of Science ®Google Scholar
• Shanks GD, Oloo AJ, Aleman GM, A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001;33:1968-74
   PubMed Web of Science ®Google Scholar
• Walsh DS, Eamsila C, Sasiprapha T, Efficacy of Monthly Tafenoquine for Prophylaxis of Plasmodium vivax and Multidrug-Resistant P. falciparum Malaria. J Infect Dis 2004;190:1456-63
   PubMed Web of Science ®Google Scholar
• Lell B, Faucher JF, Missinou MA, Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet 2000;355:2041-5
   PubMed Web of Science ®Google Scholar
• Coleman RE. Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi. Am J Trop Med Hyg 1990;42:196-205
   PubMed Web of Science ®Google Scholar
• Ponsa N, Sattabongkot J, Kittayapong P, Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg 2003;69:542-7
   PubMed Web of Science ®Google Scholar
• Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem 2007;2:944-86
   PubMed Web of Science ®Google Scholar
• Coatney GR, Mickelsen O, Burgess RW, Chloroquine or pyrimethamine in salt as a supressive against sporozoite-induced vivax malaria (Chesson strain). Bull World Health Organ 1958;19:53-67
   PubMedGoogle Scholar
• Pinotti M. The addition of antimalarial drugs to cooking salt: its importance in malaria eradication programmes. Triangle 1959;4:110-13
   PubMedGoogle Scholar
• Box ED, Box QT, Young MD. Chloroquine-resistant plasmodium falciparum from Porto Velho, Brazil. Am J Trop Med Hyg 1963;12:300-4
   PubMed Web of Science ®Google Scholar
• Contacos PG, Lunn JS, Coatney GR. Drug-resistant falciparum malaria from Cambodia and Malaya. Trans R Soc Trop Med Hyg 1963;57:417-24
   PubMedGoogle Scholar
• Young MD. Amodiaquine and hydroxychloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 1961;10:689-93
   PubMed Web of Science ®Google Scholar
• Jaeger A, Sauder P, Kopferschmitt J, Flesch F. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp 1987;2:242-73
   PubMedGoogle Scholar
• Mwai L, Ochong E, Abdirahman A, Chloroquine resistance before and after its withdrawal in Kenya. Malar J 2009;8:106
   PubMed Web of Science ®Google Scholar
• Laufer MK, Thesing PC, Eddington ND, Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 2006;355:1959-66
   PubMed Web of Science ®Google Scholar
• Yang H, Liu D, Huang K, Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1999;17:43-5
   PubMedGoogle Scholar
• Briolant S, Henry M, Oeuvray C, Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother 2010;54:3537-44
   PubMed Web of Science ®Google Scholar
• Muangnoicharoen S, Johnson DJ, Looareesuwan S, Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother 2009;53:1362-6
   PubMed Web of Science ®Google Scholar
• Eastman RT, Dharia NV, Winzeler EA, Fidock DA. Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother 2011;55:3908-16
   PubMed Web of Science ®Google Scholar
• Jansen FH.. The pharmaceutical death-ride of dihydroartemisinin. Malar J 2010;9:212
   PubMedGoogle Scholar
• Davis TME, Hung T-Y, Sim I-K, Piperaquine: a resurgent antimalarial drug. Drugs 2005;65:75-87
   PubMed Web of Science ®Google Scholar
• Schmatz, Dennis. Dihydroartemisinin: More Life-boat than Death-ride. 2010. Available from: http://www.malariajournal.com/content/9/1/212/comments
   Google Scholar
• Lell B, Ruangweerayut R, Wiesner J, Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother 2003;47:735-8
   PubMed Web of Science ®Google Scholar
• Missinou MA, Borrmann S, Schindler A, Fosmidomycin for malaria. Lancet 2002;360:1941-2
   PubMed Web of Science ®Google Scholar
• Wiesner J, Henschker D, Hutchinson DB, In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob Agents Chemother 2002;46:2889-94
   PubMed Web of Science ®Google Scholar
• Borrmann S, Adegnika AA, Matsiegui P-B, Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis 2004;189:901-8
   PubMed Web of Science ®Google Scholar
• Borrmann S, Issifou S, Esser G, Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis 2004;190:1534-40
   PubMed Web of Science ®Google Scholar
• Borrmann S, Lundgren I, Oyakhirome S, Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother 2006;50:2713-18
   PubMed Web of Science ®Google Scholar
• Ruangweerayut R, Looareesuwan S, Hutchinson D, Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria. Malar J 2008;7:225
   PubMed Web of Science ®Google Scholar
• E. P. Lindemann JPG. Jomaa Pharma GmbH. Available from: http://www.jomaa-pharma.com/news.html [Last accessed 16 December 2011]
   Google Scholar
• Fehintola FA, Adedeji AA, Sowunmi A. Comparative efficacy of chloroquine and cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in Nigerian children. Cent Afr J Med 2002;48:101-5
   PubMedGoogle Scholar
• Fehintola FA, Adedeji AA, Tambo E, Cotrimoxazole in the treatment of acute uncomplicated falciparum malaria in nigerian children: a controlled clinical trial. Clin Drug Investig 2004;24:149-55
   PubMed Web of Science ®Google Scholar
• Omar SA, Bakari A, Owiti A, Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children. Trans R Soc Trop Med Hyg 2001;95:657-60
   PubMed Web of Science ®Google Scholar
• Kilian AH, Jelinek T, Prislin I, Resistance in vivo of Plasmodium falciparum to co-trimoxazole in western Uganda. Trans R Soc Trop Med Hyg 1998;92:197-200
   PubMed Web of Science ®Google Scholar
• Jelinek T, Kilian AH, Curtis J, Plasmodium falciparum: selection of serine 108 of dihydrofolate reductase during treatment of uncomplicated malaria with co-trimoxazole in Ugandan children. Am J Trop Med Hyg 1999;61:125-30
   PubMed Web of Science ®Google Scholar
• ter Kuile FO, Parise ME, Verhoeff FH, The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004;71:41-54
   PubMed Web of Science ®Google Scholar
• Search of: Co-trimoxazole malaria - List Results - ClinicalTrials.gov. 2011. Available from: http://clinicaltrials.gov/ct2/results?term=Co-trimoxazole+malaria [Last accessed 16 December 2011]
   Google Scholar
• Yeo AE, Rieckmann KH. Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro. Int J Parasitol 1995;25:531-2
   PubMed Web of Science ®Google Scholar
• Capan M, Mombo-Ngoma G, Makristathis A, Ramharter M. Anti-bacterial activity of intermittent preventive treatment of malaria in pregnancy: comparative in vitro study of sulphadoxine-pyrimethamine, mefloquine, and azithromycin. Malar J 2010;9:303
   PubMed Web of Science ®Google Scholar
• Chico RM, Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Trop Med Int Health 2011. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21477099 [Last accessed 26 April 2011]
   Google Scholar
• Chico RM, Pittrof R, Greenwood B, Chandramohan D. Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar J 2008;7:255
   PubMed Web of Science ®Google Scholar
• Rottmann M, McNamara C, Yeung BKS, Spiroindolones, a potent compound class for the treatment of malaria. Science 2010;329:1175-80
   PubMed Web of Science ®Google Scholar
• V Pelt-Koops JC, Pett HE, Graumans W, The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector. Antimicrobial Agents and Chemotherapy. 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22508309 [Last accessed 22 May 2012]
   Google Scholar
• NITD 609 MMV. Available from: http://www.mmv.org/research-development/project-portfolio/nitd-609 [Last accessed 18 April 2011]
   Google Scholar
• Schwarz NG, Oyakhirome S, Potschke M, 5-day nonobserved artesunate monotherapy for treating uncomplicated Falciparum malaria in young Gabonese children. Am J Trop Med Hyg 2005;73:705-9
   PubMed Web of Science ®Google Scholar
• Hamel MJ, Greene C, Chiller T, Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 2008;79:320-30
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Fateye BA, Adedeji AA, Effects of antifolates–co-trimoxazole and pyrimethamine-sulfadoxine–on gametocytes in children with acute, symptomatic, uncomplicated, Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz 2005;100:451-5
   PubMed Web of Science ®Google Scholar
• Beavogui AH, Djimde AA, Gregson A, Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol 2010;40:1213-20
   PubMed Web of Science ®Google Scholar
• Zwang J, Ashley EA, Karema C, Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009;4:e6358
   PubMed Web of Science ®Google Scholar